Lobbyist Public Search

Records prior to registration year 2005 are not available online. Contact the Lobbyist Division here for assistance.	Search data is collected from registration records and disclosure reports submitted by lobbyists, lobbying entities, and their clients. Massachusetts General Law requires any party providing or retaining lobbying services to register annually, and submit disclosure reports twice a year.
	Your comments are welcome: submit feedback

Disclosure reporting details

Back to search detail summary

Lobbyist disclosure reporting period: 01/01/2014 - 06/30/2014

Lobbyist name	Mark O'Rourke
Business name	Astellas Pharma US, Inc.
Address	55 Railroad Place Unit 401
City, state, zip code	Saratoga Springs, NY 12866
Country	US
Agent type	Both
Phone	518-871-1716

Operating Expenses

Date	Type of expense	Amount
1/1/2014-6/30/2014	Advertising expenses	$0.00
1/1/2014-6/30/2014	Photocopies, scans	$0.00
1/1/2014-6/30/2014	Computer equipment, supplies	$0.00
1/1/2014-6/30/2014	Professional dues	$0.00
1/1/2014-6/30/2014	Fax charges	$0.00
1/1/2014-6/30/2014	Internet fees	$0.00
1/1/2014-6/30/2014	Legal fees	$0.00
1/1/2014-6/30/2014	Postage, shipping, delivery	$0.00
1/1/2014-6/30/2014	Office supplies, equipment	$0.00
1/1/2014-6/30/2014	Printing expenses	$0.00
1/1/2014-6/30/2014	Public relations expenses	$0.00
1/1/2014-6/30/2014	Rent	$0.00
1/1/2014-6/30/2014	Office and support staff salaries	$0.00
1/1/2014-6/30/2014	Professional subscriptions	$0.00
1/1/2014-6/30/2014	Taxes	$0.00
1/1/2014-6/30/2014	Telephone, cell phone, handheld	$0.00
1/1/2014-6/30/2014	Utilities (heat, water, electricity)	$0.00
1/1/2014-6/30/2014	Other operating expenses	$0.00
	Total operating expenses	$0.00

Activities, Bill Numbers and Titles

Client: Astellas Pharma US, Inc.

House / Senate	Bill Number or Agency Name	Bill title or activity	Agent position	Amount	Direct business association
House Bill	4000	An Act making appropriations for the fiscal year 2015 for maintenance of the Departments, Boards, Commissions, Institutions, and Certain Activities of the Commonwealth, for interest, Sinking Fund and Serial Bond Requirements and for Certain Permanent Improvements.	Support	$371.97	I had no business association with any public official I lobbied during this reporting period.
House Bill	3734	An Act relative to the substitution of interchangeable biosimilars.	Neutral	$371.97	I had no business association with any public official I lobbied during this reporting period.
Senate Bill	1051	An Act to prevent undue influence on perscriber behavior.	Oppose	$371.97	I had no business association with any public official I lobbied during this reporting period.
House Bill	2082	An Act establishing a statewide discount program for pharmaceuticals.	Oppose	$371.97	I had no business association with any public official I lobbied during this reporting period.
Senate Bill	2176	An Act relative to the substitution of interchangeable biosimilars.	Neutral	$371.97	I had no business association with any public official I lobbied during this reporting period.
House Bill	2018	An Act to define modest meals and refreshments in prescriber education settings.	Oppose	$371.97	I had no business association with any public official I lobbied during this reporting period.
Senate Bill	2160	Text of the Senate amendment to the House Bill making appropriations for the fiscal year 2015 for the maintenance of the Departments, Boards, Commissions, Institutions, and certain activities of the Commonwealth, for interest, Sinking Fund and Serial Bond Requirements and for Certain Permanent Improvements.	Oppose	$371.98	I had no business association with any public official I lobbied during this reporting period.
House Bill	2061	An Act prohibiting advertising by pharmaceutical companies.	Oppose	$371.97	I had no business association with any public official I lobbied during this reporting period.
House Bill	4001	An Act making appropriations for the fiscal year 2015 for maintenance of the Departments, Boards, Commissions, Institutions, and Certain Activities of the Commonwealth, for interest, Sinking Fund and Serial Bond Requirements and for Certain Permanent Improvements.	Support	$371.97	I had no business association with any public official I lobbied during this reporting period.
Executive		Chapter 143 of the Acts of 2014	Neutral	$371.97	I had no business association with any public official I lobbied during this reporting period.
House Bill	3667	An Act relative to the substitution of interchangeable biosimilars.	Neutral	$371.97	I had no business association with any public official I lobbied during this reporting period.
House Bill	2020	An Act to reduce health care costs by promoting non-biased prescriber information.	Oppose	$371.97	I had no business association with any public official I lobbied during this reporting period.
House Bill	4001	Text of the recommended amendment (Ways and Means) to the House Bill making appropriations for the fiscal year 2015 for the maintenance of the Departments, Boards, Commissions, Institutions, and certain activities of the Commonwealth, for interest, Sinking Fund and Serial Bond Requirements and for Certain Permanent Improvements.	Oppose	$371.98	I had no business association with any public official I lobbied during this reporting period.
House Bill	1927	An Act relative to the substitution of interchangeable biosimilars.	Neutral	$371.97	I had no business association with any public official I lobbied during this reporting period.
			Total amount	$5,207.60

Meals, Travel, and Entertainment Expenses

No meals, travel, or entertainment expenses were filed for this disclosure reporting period.

Additional Expenses

No additional expenses were filed for this disclosure reporting period.

Campaign Contributions

Date	Recipient name	Office sought	Amount
04/15/2014	Representative Joseph F. Wagner	State Representative; 8th Hampden / Chicopee	$200.00
05/21/2014	Representative Brian S. Dempsey	State Representative; 3rd Essex / Haverhill	$200.00
06/26/2014	Warren Tolman	Democratic Candidate for Massachusetts Attorney General	$200.00
		Total contributions	$600.00

Close this page

Terms and Conditions Accessibility Statement

Connect with Us